Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor

Breast Cancer Research and Treatment

Volumn 63, Issue 3, 2000, Pages 235-241

  Kwasny, W ^a   Kornek, G ^a   Haider, K ^a   Valencak, J ^a   Ulrich Pur, H ^a   Penz, M ^a   Lang, F ^a   Depisch, D ^a   Scheithauer, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Advanced breast cancer; Chemotherapy; Cyclophosphamide; Docetaxel; Epirubicin; G CSF; Second line

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; METHOTREXATE; NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTICEMIA; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; PACLITAXEL; TAXOIDS;

EID: 0033729902     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006421901192     Document Type: Article

References (21)

1. Patterns of relapse and survival following radical mastectomy
2. Treatment of metastatic disease: Hormonal therapy and chemotherapy
3. Doxorubicin/taxane combinations: Cardiac toxicity and pharmacokinetics
4. Dose response-relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial
5. 2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer
6. Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind
7. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy
8. Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: From metastatic to adjuvant setting
9. Combination versus sequential doxorubicin and docetaxel for breast cancer: A randomized pilot trial of the Hoosier Oncology Group
10. Reporting results of cancer treatment
11. The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent
12. Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis
13. Non-parametric estimation from incomplete observations
14. Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor
15. Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and 1-leucovorin plus human granulocyte colony-stimulating factor
16. Docetaxel: An update of its use in advanced breast cancer
17. Docetaxel (Taxotere) plus doxorubicin-based combinations: The evidence of activity in breast cancer
18. Docetaxel in combination with doxorubicin: A phase I dose-finding study
19. Phase II study of docetaxel in combination with doxorubicin as 1st line chemotherapy of metastatic breast cancer
20. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology Group study (El 196)
21. Final results of a phase II study of docetaxel, doxorubicin and cyclophosphamide (TAC) as 1st-line chemotherapy in metastatic breast cancer patients